Market Summary
USD17.78-0.40
Market Closed-2.20%
NVCR Stock Price
NVCR RSI Chart
NVCR Valuation
NVCR Price/Sales (Trailing)
NVCR Profitability
NVCR Fundamentals
NVCR Revenue
NVCR Earnings
Price Action
52 Week Range
17.73120.03
(Low)(High)
Last 7 days
-10.8%
Last 30 days
-42.9%
Last 90 days
-59.9%
Trailing 12 Months
-78.4%
NVCR Financial Health
NVCR Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for NVCR
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-01 | Cordova Ashley | sold | -19,264 | 21.8172 | -883 | chief financial officer |
2023-09-01 | Shah Pritesh | sold | -5,956 | 21.8172 | -273 | chief growth officer |
2023-09-01 | GROENHUYSEN WILHELMUS CM | sold | -6,414 | 21.8172 | -294 | chief operating officer |
2023-08-02 | Cordova Ashley | sold | -34,607 | 30.2511 | -1,144 | chief financial officer |
2023-06-30 | Weinberg Uri | acquired | 10,760 | 35.28 | 305 | chief innovation officer |
2023-06-30 | Shah Pritesh | acquired | 12,947 | 35.28 | 367 | chief growth officer |
2023-06-30 | Burke William Patrick | acquired | 12,595 | 35.28 | 357 | chief human resources officer |
2023-06-30 | Ben Arye Barak | acquired | 10,160 | 35.28 | 288 | general counsel |
2023-06-30 | Cordova Ashley | acquired | 12,947 | 35.28 | 367 | chief financial officer |
2023-06-30 | GROENHUYSEN WILHELMUS CM | acquired | 12,912 | 35.28 | 366 | chief operating officer |
Which funds bought or sold NVCR recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-13 | CGC Financial Services, LLC | new | - | 1,245 | 1,245 | -% |
2023-09-12 | Farther Finance Advisors, LLC | new | - | 166 | 166 | -% |
2023-08-23 | WOLVERINE TRADING, LLC | new | - | 271,031 | 271,031 | -% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -2.49 | -3,174,040 | 6,527,870 | 0.01% |
2023-08-21 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | unchanged | - | -1,766,000 | 3,934,000 | 0.04% |
2023-08-21 | OSAIC HOLDINGS, INC. | reduced | -4.56 | -163,918 | 312,290 | -% |
2023-08-16 | Nuveen Asset Management, LLC | reduced | -1.53 | -5,809,210 | 12,315,800 | -% |
2023-08-16 | Thomas J. Herzfeld Advisors, Inc. | sold off | -100 | -1,323 | - | -% |
2023-08-16 | Sunbelt Securities, Inc. | reduced | -36.17 | -1,492 | 1,245 | -% |
2023-08-15 | BENJAMIN F. EDWARDS & COMPANY, INC. | sold off | -100 | -8,000 | - | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Novocure
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 13, 2023 | capital international investors | 7.8% | 8,155,909 | SC 13G/A | |
| Feb 13, 2023 | capital world investors | 12.3% | 12,899,395 | SC 13G/A | |
| Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 9.10% | 9,547,336 | SC 13G/A | |
| Jan 31, 2023 | blackrock inc. | 7.2% | 7,605,425 | SC 13G/A | |
| Jan 23, 2023 | baillie gifford & co | 8.45% | 8,863,842 | SC 13G/A | |
| Apr 11, 2022 | fmr llc | - | 0 | SC 13G/A | |
| Feb 11, 2022 | capital world investors | 12.3% | 12,723,214 | SC 13G/A | |
| Feb 11, 2022 | capital international investors | 11.1% | 11,531,075 | SC 13G/A | |
| Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A |
Recent SEC filings of Novocure
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 05, 2023 | 4 | Insider Trading | |
| Sep 05, 2023 | 4 | Insider Trading | |
| Sep 05, 2023 | 4 | Insider Trading | |
| Sep 01, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 28, 2023 | 8-K | Current Report | |
| Aug 04, 2023 | 4 | Insider Trading | |
| Jul 27, 2023 | 8-K | Current Report | |
| Jul 27, 2023 | 10-Q | Quarterly Report | |
| Jul 21, 2023 | 8-K | Current Report | |
| Jul 06, 2023 | 4 | Insider Trading |
Peers (Alternatives to Novocure)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
SYK | 109.7B | 19.5B | 4.61% | 32.58% | 40.5 | 5.64 | 10.36% | 30.30% |
ISRG | 102.6B | 6.7B | 1.85% | 46.31% | 71.98 | 15.39 | 11.75% | -0.66% |
BSX | 78.2B | 13.4B | 7.30% | 33.81% | 85.79 | 5.84 | 8.69% | 3.17% |
BDX | 71.3B | 19.0B | -3.08% | 10.26% | 44.09 | 3.79 | 0.46% | -5.24% |
EW | 43.7B | 5.7B | -5.74% | -17.48% | 31.48 | 7.73 | 5.64% | -4.53% |
| MID-CAP | ||||||||
PEN | 10.1B | 937.8M | 5.52% | 36.72% | 345.25 | 10.72 | 16.30% | 250.21% |
SWAV | 7.5B | 616.6M | -7.14% | -29.65% | 30.68 | 12.13 | 69.52% | 343.68% |
GMED | 5.3B | 1.1B | -4.57% | -12.56% | 25.23 | 4.84 | 12.63% | 50.85% |
IRTC | 2.7B | 452.1M | -16.85% | -42.51% | -27.51 | 6.04 | 24.99% | 24.09% |
TNDM | 1.5B | 790.3M | -18.06% | -57.30% | -6.6 | 1.87 | 3.21% | -1604.53% |
| SMALL-CAP | ||||||||
ATEC | 1.6B | 421.8M | -8.54% | 49.60% | -9.62 | 3.81 | 44.49% | -2.43% |
AVNS | 952.1M | 780.7M | -7.00% | -11.88% | -26.45 | 1.22 | 4.68% | -510.17% |
CSII | 839.3M | 239.8M | 0.70% | 0.15% | -22.16 | 3.5 | -4.74% | -31.15% |
SILK | 620.2M | 162.9M | -26.12% | -63.06% | -11.73 | 3.81 | 42.67% | 12.82% |
Novocure News
Returns for NVCR
Cumulative Returns on NVCR
10.5%
7-Year Cumulative Returns
-18.2%
5-Year Cumulative Returns
-45.6%
3-Year Cumulative Returns
Risks for NVCR
What is the probability of a big loss on NVCR?
99.6%
Probability that Novocure stock will be more than 20% underwater in next one year
89.6%
Probability that Novocure stock will be more than 30% underwater in next one year.
53.5%
Probability that Novocure stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does NVCR drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Novocure was unfortunately bought at previous high price.
Drawdowns
Financials for Novocure
Income Statement (Last 12 Months)(In Millions)
| Income Statement (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | -2.8% | 508 | 522 | 538 | 543 | 545 | 538 | 535 | 546 | 545 | 527 | 494 | 450 | 409 | 380 | 351 | 322 | 294 | 269 | 248 | 232 | 217 |
| Gross Profit | -5.0% | 385 | 406 | 423 | 427 | 429 | 422 | 420 | 432 | 433 | 419 | 388 | 346 | 311 | 287 | 263 | 235 | 212 | 188 | 168 | 159 | 149 |
| Operating Expenses | 3.8% | 576 | 555 | 512 | 497 | 483 | 467 | 464 | 441 | 419 | 385 | 357 | 328 | 304 | 285 | 264 | 245 | 230 | 215 | 202 | 189 | 179 |
| S&GA Expenses | 7.3% | 201 | 187 | 174 | 163 | 154 | 144 | 137 | 129 | 126 | 121 | 118 | 113 | 108 | 103 | 97.00 | 91.00 | 86.00 | 82.00 | 78.00 | 72.00 | 70.00 |
| R&D Expenses | -0.7% | 222 | 224 | 206 | 208 | 204 | 198 | 201 | 188 | 173 | 153 | 132 | 112 | 98.00 | 87.00 | 79.00 | 70.00 | 65.00 | 57.00 | 51.00 | 46.00 | 42.00 |
| EBITDA | 100.0% | - | -102 | -63.54 | -64.17 | -51.21 | -41.26 | -41.72 | -7.60 | 15.00 | 36.00 | 36.00 | 29.00 | 21.00 | 16.00 | 13.00 | - | - | - | - | - | - |
| EBITDA Margin | 100.0% | - | -0.20* | -0.12* | -0.12* | -0.09* | -0.08* | -0.08* | -0.01* | 0.03* | 0.07* | 0.07* | 0.06* | 0.05* | 0.04* | 0.04* | - | - | - | - | - | - |
| Interest Expenses | 75.2% | 26.00 | 15.00 | 8.00 | -3.84 | -3.84 | -1.61 | 0.00 | 0.00 | 2.00 | 5.00 | 9.00 | 12.00 | 14.00 | 14.00 | 14.00 | 14.00 | 14.00 | 14.00 | 13.00 | 12.00 | 12.00 |
| Earnings Before Taxes | -23.4% | -160 | -130 | -81.85 | -74.86 | -61.98 | -51.86 | -52.07 | -17.68 | 4.00 | 21.00 | 18.00 | 8.00 | -2.05 | -6.15 | -8.82 | -18.06 | -27.00 | -36.90 | -45.94 | -42.01 | -42.44 |
| EBT Margin | 100.0% | - | -0.25* | -0.15* | -0.14* | -0.11* | -0.10* | -0.10* | -0.03* | 0.01* | 0.04* | 0.04* | 0.02* | -0.01* | -0.02* | -0.03* | - | - | - | - | - | - |
| Net Income | -23.7% | -174 | -140 | -92.53 | -81.69 | -68.24 | -58.87 | -58.35 | -26.98 | -4.57 | 12.00 | 20.00 | 19.00 | 12.00 | 9.00 | -7.23 | -27.12 | -40.74 | -54.98 | -63.56 | -58.87 | -58.68 |
| Net Income Margin | 100.0% | - | -0.27* | -0.17* | -0.15* | -0.13* | -0.11* | -0.11* | -0.05* | -0.01* | 0.02* | 0.04* | 0.04* | 0.03* | 0.02* | -0.02* | - | - | - | - | - | - |
| Free Cashflow | 100.0% | - | -4.61 | 9.00 | 20.00 | 24.00 | 36.00 | 59.00 | 106 | 113 | 99.00 | 84.00 | 40.00 | 24.00 | 22.00 | 16.00 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | -1.3% | 1,159 | 1,174 | 1,192 | 1,174 | 1,163 | 1,150 | 1,139 | 1,120 | 1,097 | 1,068 | 1,052 | 431 | 529 | 502 | 479 | 444 | 406 | 370 | 340 | 316 | 310 |
| Current Assets | -2.2% | 1,065 | 1,089 | 1,112 | 1,102 | 1,095 | 1,081 | 1,074 | 1,069 | 1,046 | 1,015 | 999 | 383 | 488 | 462 | 440 | 407 | 370 | 336 | 321 | 297 | 290 |
| Cash Equivalents | -15.9% | 157 | 187 | 115 | 244 | 368 | 192 | 210 | 691 | 361 | 326 | 246 | 235 | 198 | 183 | 179 | 210 | 182 | 154 | 143 | 125 | 117 |
| Inventory | 4.1% | 33.00 | 32.00 | 29.00 | 27.00 | 30.00 | 29.00 | 24.00 | 23.00 | 27.00 | 28.00 | 27.00 | 26.00 | 26.00 | 23.00 | 24.00 | 24.00 | 25.00 | 24.00 | 23.00 | 22.00 | 20.00 |
| Net PPE | 12.9% | 41.00 | 36.00 | 33.00 | 30.00 | 27.00 | 25.00 | 23.00 | 12.00 | 12.00 | 12.00 | 11.00 | 10.00 | 11.00 | 10.00 | 9.00 | 8.00 | 8.00 | 8.00 | 8.00 | 9.00 | 9.00 |
| Liabilities | 0.2% | 743 | 742 | 750 | 729 | 721 | 714 | 729 | 707 | 700 | 695 | 575 | 124 | 261 | 261 | 262 | 253 | 247 | 244 | 228 | 201 | 198 |
| Current Liabilities | 0.9% | 150 | 149 | 159 | 141 | 135 | 128 | 143 | 125 | 116 | 110 | 114 | 95.00 | 85.00 | 84.00 | 86.00 | 80.00 | 74.00 | 71.00 | 65.00 | 48.00 | 45.00 |
| LT Debt, Non Current | 0.1% | 567 | 566 | 566 | 565 | 564 | 563 | 562 | 561 | 561 | 560 | 430 | - | 150 | 149 | 149 | 149 | 149 | 149 | 149 | 149 | 149 |
| Shareholder's Equity | -3.8% | 416 | 432 | 441 | 445 | 442 | 436 | 410 | 413 | 397 | 372 | 477 | 307 | 268 | 242 | 218 | 190 | 159 | 126 | 112 | 115 | 112 |
| Retained Earnings | -6.9% | -888 | -831 | -778 | -741 | -714 | -690 | -685 | -659 | -646 | -631 | -631 | -635 | -645 | -646 | -650 | -655 | -657 | -655 | -643 | -628 | -616 |
| Additional Paid-In Capital | 3.2% | 1,307 | 1,266 | 1,222 | 1,189 | 1,158 | 1,128 | 1,100 | 1,074 | 1,045 | 1,006 | 1,111 | 946 | 917 | 893 | 871 | 848 | 818 | 784 | 757 | 744 | 730 |
| Shares Outstanding | 0.4% | 107 | 106 | 105 | 105 | 105 | 104 | 104 | 104 | 103 | 103 | 102 | 101 | 101 | 100 | 99.00 | 98.00 | 96.00 | 95.00 | 93.00 | 93.00 | 91.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | -216.9% | -20.75 | 18.00 | 31.00 | 49.00 | 51.00 | 61.00 | 83.00 | 122 | 128 | 115 | 99.00 | 53.00 | 37.00 | 33.00 | 27.00 | 36.00 | 27.00 | 11.00 | -1.86 | -21.58 | -24.67 |
| Share Based Compensation | 5.7% | 128 | 121 | 107 | 100 | 99.00 | 101 | 95.00 | 93.00 | 87.00 | 78.00 | 76.00 | 70.00 | 64.00 | 59.00 | 52.00 | 48.00 | 45.00 | 41.00 | 40.00 | 36.00 | 34.00 |
| Cashflow From Investing | -421.4% | -209 | -40.26 | -139 | -510 | -58.04 | -216 | -144 | -259 | -414 | -415 | -472 | 94.00 | -55.36 | -53.79 | -51.67 | -6.70 | -5.53 | -4.62 | -5.49 | -5.65 | -6.40 |
| Cashflow From Financing | 15.8% | 20.00 | 18.00 | 15.00 | 16.00 | 15.00 | 21.00 | 26.00 | 593 | 449 | 444 | 440 | -122 | 34.00 | 49.00 | 62.00 | 56.00 | 44.00 | 35.00 | 69.00 | 68.00 | 66.00 |
NVCR Income Statement
2023-06-30CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | Dec. 31, 2022 | |
| Income Statement [Abstract] | |||||
| Net revenues | $ 126,051 | $ 140,866 | $ 248,233 | $ 278,413 | $ 537,840 |
| Cost of revenues | 34,018 | 28,503 | 63,632 | 56,230 | 114,867 |
| Gross profit | 92,033 | 112,363 | 184,601 | 222,183 | 422,973 |
| Operating costs and expenses: | |||||
| Research, development and clinical studies | 55,427 | 57,075 | 115,131 | 99,309 | 206,085 |
| Sales and marketing | 58,488 | 44,750 | 109,657 | 82,634 | 173,658 |
| General and administrative | 40,778 | 31,666 | 82,722 | 62,174 | 132,753 |
| Total operating costs and expenses | 154,693 | 133,491 | 307,510 | 244,117 | 512,496 |
| Operating income (loss) | (62,660) | (21,128) | (122,909) | (21,934) | (89,523) |
| Financial income (expenses), net | 8,756 | (2,228) | 17,925 | (3,937) | 7,677 |
| Income (loss) before income tax | (53,904) | (23,356) | (104,984) | (25,871) | (81,846) |
| Income tax | 3,514 | 652 | 5,495 | 2,784 | 10,688 |
| Net income (loss) | $ (57,418) | $ (24,008) | $ (110,479) | $ (28,655) | $ (92,534) |
| Basic net income (loss) per ordinary share (in usd per share) | $ (0.54) | $ (0.23) | $ (1.04) | $ (0.27) | $ (0.88) |
| Diluted net income (loss) per ordinary share (in usd per share) | $ (0.54) | $ (0.23) | $ (1.04) | $ (0.27) | $ (0.88) |
| Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares) | 106,289,073 | 104,627,789 | 105,979,791 | 104,408,164 | 104,660,476 |
| Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares) | 106,289,073 | 104,627,789 | 105,979,791 | 104,408,164 | 104,660,476 |
NVCR Balance Sheet
2023-06-30CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| CURRENT ASSETS: | ||
| Cash and cash equivalents | $ 156,978 | $ 115,326 |
| Short-term investments | 783,837 | 854,099 |
| Restricted cash | 516 | 508 |
| Trade receivables, net | 70,988 | 86,261 |
| Receivables and prepaid expenses | 20,148 | 25,959 |
| Inventories | 33,023 | 29,376 |
| Total current assets | 1,065,490 | 1,111,529 |
| LONG-TERM ASSETS: | ||
| Property and equipment, net | 41,156 | 32,678 |
| Field equipment, net | 11,519 | 12,684 |
| Right-of-use assets | 26,278 | 23,596 |
| Other long-term assets | 14,572 | 11,161 |
| Total long-term assets | 93,525 | 80,119 |
| TOTAL ASSETS | 1,159,015 | 1,191,648 |
| CURRENT LIABILITIES: | ||
| Trade payables | 82,536 | 85,197 |
| Other payables, lease liabilities and accrued expenses | 67,551 | 73,580 |
| Total current liabilities | 150,087 | 158,777 |
| LONG-TERM LIABILITIES: | ||
| Long-term debt, net | 567,150 | 565,509 |
| Deferred revenues | 807 | 2,878 |
| Long-term leases | 20,329 | 18,762 |
| Employee benefit liabilities | 4,840 | 4,404 |
| Other long-term liabilities | 119 | 148 |
| Total long-term liabilities | 593,245 | 591,701 |
| TOTAL LIABILITIES | 743,332 | 750,478 |
| COMMITMENTS AND CONTINGENCIES | ||
| SHAREHOLDERS' EQUITY: | ||
| Ordinary shares no par value, unlimited shares authorized; issued and outstanding: 106,605,331 shares and 105,049,411 shares at June 30, 2023 (unaudited) and December 31, 2022, respectively | 0 | 0 |
| Additional paid-in capital | 1,306,603 | 1,222,063 |
| Accumulated other comprehensive income (loss) | (1,981) | (2,433) |
| Retained earnings (accumulated deficit) | (888,939) | (778,460) |
| TOTAL SHAREHOLDERS' EQUITY | 415,683 | 441,170 |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $ 1,159,015 | $ 1,191,648 |
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields (TTFields) devices for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and malignant pleural mesothelioma. The company markets its products in the European Union, the United Kingdom, Japan, and internationally. It has a clinical study collaboration agreement with MSD to study TTFields together with KEYNOTE, an anti-PD-1 therapy; and a strategic collaboration with Zai Lab (Shanghai) Co., Ltd. to commercialize its products in Greater China and establishes a development partnership intended to accelerate the development of TTFields in multiple solid tumor cancer indications. NovoCure Limited was incorporated in 2000 and is based in Saint Helier, Jersey.